Chronic Obstructive Pulmonary Disease Market Size Worth $31.29 Billion By 2032 | CAGR: 4.40%

The chronic obstructive pulmonary disease market size is expected to reach USD 31.29 billion by 2032, according to a new study by Polaris Market Research. The report " Chronic Obstructive Pulmonary Disease Market Size, Trends, Industry Analysis Report, By Drug Type; By Product Type; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

A long-lasting inflammatory lung condition that impairs lung airflow is a chronic obstructive pulmonary disease (COPD). Wheezing, coughing, mucus production, and breathing problems are just signs and symptoms of PD. The two main types of COPD are chronic bronchitis and emphysema, and the four phases of chronic obstructive pulmonary disease (COPD) are mild to highly severe.

One significant reason anticipated to accelerate the growth and demand of the chronic obstructive pulmonary disease market is the increase in COPD cases among the global population. In addition, the young population's intake of alcohol and tobacco is increasing, and more people are becoming aware of COPD and its treatment. COPD could develop as a result of tobacco use. Around the world, there are more and more adults who are dependent on cigarettes. Workplace air pollution and other risk factors are both present. The WHO states that cigarette smoke exposure is the leading cause of COPD.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-chronic-obstructive-pulmonary-disease-market/request-for-sample

Smoking is the primary environmental risk factor for COPD, although other exposures to the environment, such as those to air pollution and biomass fuels, may also be involved. In addition to disclosures, host factors can put people at risk for COPD. Some are accelerated aging, improper lung development, and aberrant genetics.

For instance, In January 2022, a phase 4 trial comparing Yuperli (revefenacin) with Spiriva (tiotropium) was conducted to improve lung health in persons with COPD. Theravance Biopharma and Mylan (Viatris) worked together to create it. You can use a nebulizer to inhale this solution.

Chronic Obstructive Pulmonary Disease Market Report Highlights

• By drug type, bronchodilator segment is expected to increase over a forecast period due to increased cases of COPD and asthma.
• Nebulizers segment is expected to grow rapidly in the market over the forecast period due to new technologies invented in nebulizers.
• The need for cutting-edge medicines, the rise of the healthcare infrastructure, and more government funding are expected to positively impact the North American market and contribute to its expansion.
• The major international participants include AstraZeneca, Orion Corporation, Novartis, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Mylan (Viatris), CHIESI Farmaceutici SpA and others.

Polaris Market Research has segmented chronic obstructive pulmonary disease market report based on drug type, product type, and region:

Chronic obstructive pulmonary disease, by Drug Type (Revenue - USD Billion, 2019-2032)

• Phosphodiesterase-4 Inhibitor
• Bronchodilators

• Long-Acting Bronchodilators
• Short-Acting Bronchodilators

• Methylxanthines
• Corticosteroids

Chronic obstructive pulmonary disease, by Product Type (Revenue - USD Billion, 2019-2032)

• Inhalers

• Dry Powders Inhalers
• Metered-Dose Inhalers
• Soft Mist Inhalers

• Nebulizers

• Ultrasonic Nebulizers
• Jet Nebulizers

Chronic obstructive pulmonary disease, by Region (Revenue - USD Billion, 2019-2032)

• North America

• U.S.
• Canada

• Europe

• Netherland
• Spain
• Russia
• Italy
• UK
• France
• Germany

• Asia Pacific

• Malaysia
• Indonesia
• Japan
• China
• India
• South Korea

• Latin America

• Argentina
• Mexico
• Brazil

• Middle East & Africa

• Saudi Arabia
• UAE
• South Africa
• Israel